AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Ipsen Share Issue/Capital Change 2018

Jan 2, 2018

1449_iss_2018-01-02_9c4ad00c-1c55-4b6d-a3dc-34e8d4115383.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Ipsen announces it is no longer eligible for the PEA-PME scheme

Paris (France), 2 January 2018 - Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.

As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.

Consequently, Ipsen Group's securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales close to €1.6 billion in 2016, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms, and centers located in the heart of leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,100 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.

For further information:

Media Ian Weatherhead Vice-President, Corporate External communications Tél.: +44 (0) 7584230549 E-mail: [email protected]

Financial Community Eugenia Litz Vice-President Investor Relations Tel.: +44 (0) 1753 627721 E-mail: [email protected]